Physician profile
Daniel Lee
NPI 1538485271
$3,074.92
in general payments reported to CMS, 2019-2025
33 companies · $483 in 2025
The $483 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $186 · 2021: $764 · 2022: $533 · 2023: $365 · 2024: $297 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.76 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.52 | 2019-2023 | |
| Astellas Pharma US INC | $337.08 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $278.88 | 2019-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $188.90 | 2022-2025 | |
| Shield Therapeutics INC | $139.77 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $128.66 | 2021-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Exeltis, USA INC. | $119.75 | 2019-2025 | Slynd |
| Biogen, INC. | $114.14 | 2024-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $107.68 | 2019 | |
| Intuitive Surgical, INC. | $105.70 | 2023-2025 | Da Vinci Surgical System |
| Aspira Women'S Health INC | $82.76 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.70 | 2019-2024 | |
| Karl Storz Endoscopy-America | $77.68 | 2022 | |
| Avanos Medical | $71.27 | 2019 | |
| Agile Therapeutics, INC. | $62.25 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $44.87 | 2021-2022 | |
| Scynexis, INC. | $34.29 | 2022 | |
| Glaxosmithkline, LLC. | $32.88 | 2021 | |
| Organon LLC | $30.14 | 2021-2025 | Jada System |
| Therapeuticsmd, INC. | $25.12 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $19.68 | 2024 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.60 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.74 | 2022 | |
| Axonics, INC. | $16.58 | 2021 | |
| Avion Pharmaceuticals | $15.28 | 2019 | |
| Novo Nordisk INC | $15.26 | 2021 | |
| Lupin INC. | $14.75 | 2021 | |
| Medtronic, INC. | $14.04 | 2023 | Truclear |
| Millicent US INC | $13.97 | 2025 | Femlyv, Intrarosa |
| Coopersurgical, INC. | $13.08 | 2022 | |
| Merck Sharp & Dohme LLC | $12.93 | 2019 | |
| Assertio Therapeutics, INC. | $12.02 | 2020 | |
| Allergan, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.